Ultragenyx Pharmaceutical News

Analysts' Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Illumina (ILMN)

TipRanksMay 8 13:01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)

TipRanksMay 8 12:41

Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference

NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and

GlobeNewswireMay 8 04:30

Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity

Ultragenyx Pharma Is Maintained at Buy by Canaccord Genuity

Dow JonesMay 7 01:45

Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $109

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical with a Buy and lowers the price target from $111 to $109.

Analyst UpgradesMay 7 01:35

Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Results

Yahoo FinanceMay 4 22:05

Ultragenyx Pharmaceutical(RARE.US) Officer Sells US$15,455.64 in Common Stock

$Ultragenyx Pharmaceutical(RARE.US)$ Officer Crombez Eric sold 354 shares of common stock on May 2, 2024 at an average price of $43.66 for a total value of $15,455.64.Source: Announcement What is stat

Futu NewsMay 4 04:05

Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...

Yahoo FinanceMay 4 03:01

Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $107 Price Target

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains $107 price target.

BenzingaMay 3 23:14

Earnings Call Summary | Ultragenyx Pharmaceutical(RARE.US) Q1 2024 Earnings Conference

The following is a summary of the Ultragenyx Pharmaceutical, Inc. (RARE) Q1 2024 Earnings Call Transcript:Financial Performance:Ultragenyx reported Q1 2024 revenue of $109 million, with substantial co

Futu NewsMay 3 22:03 · Conference Call

Ultragenyx Pharma Is Maintained at Neutral by Wedbush

Ultragenyx Pharma Is Maintained at Neutral by Wedbush

Dow JonesMay 3 21:43

Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $47

Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical with a Neutral and lowers the price target from $48 to $47.

Analyst UpgradesMay 3 21:33

Truist Financial Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TipRanksMay 3 19:30

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Amgen (AMGN) and Zimmer Biomet Holdings (ZBH)

TipRanksMay 3 18:47

Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ...

Yahoo FinanceMay 3 05:49

Ultragenyx Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.

Ultragenyx Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.

BenzingaMay 3 05:23

Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q1 Revenue $108.8M

04:01 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q1 Revenue $108.8M

MT NewswiresMay 3 04:01

Ultragenyx Pharma 1Q Loss/Shr $2.03 >RARE

Ultragenyx Pharma 1Q Loss/Shr $2.03 >RARE

Dow JonesMay 3 04:00

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating setrusumab

GlobeNewswireApr 30 20:00

Ultragenyx Pharmaceutical: Strong Buy Rating on Growth Prospects and Pipeline Potential

TipRanksApr 30 18:21